Evidence map›Paper›PMID 36377922›Full record

ArticleMicrobiology spectrum2022

Emergence and Genomic Characterization of Neisseria gonorrhoeae Isolates with High Levels of Ceftriaxone and Azithromycin Resistance in Guangdong, China, from 2016 to 2019.

Xiaomian Lin, Wentao Chen, Yuqi Yu, Yinyuan Lan, Qinghui Xie, Yiwen Liao, Xingzhong Wu, Sanmei Tang, Xiaolin Qin, Heping Zheng

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Antibacterial potential of danthron, embelin, sanguinarine and shikonin against multidrug-resistant Neisseria gonorrhoeae in vitro.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiaomian Lin *Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.ORCID 0000-0002-7780-0458
Wentao Chen *Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.ORCID 0000-0002-4062-3865
Yuqi Yu *Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Yinyuan LanDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Qinghui XieDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Yiwen LiaoDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Xingzhong WuDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Sanmei TangDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Xiaolin QinDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Heping ZhengDermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Southern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, antibiotic resistance (especially ceftriaxone and azithromycin dual resistance) in Neisseria gonorrhoeae is the main obstacle affecting the efficacy of treatment. As analysis of drug sensitivity, molecular features, and dissemination of dual-resistant strains is important for gonococcal prevention and control, MIC, genotyping, and genome analysis were conducted to reveal the molecular characteristics and phylogeny of N. gonorrhoeae isolates. During 2016 to 2019, 5 out of 4,113 strains were defined as dual-resistant clones, with ceftriaxone MICs of 0.25 to ≥1 mg/L and azithromycin MICs of 2 to ≥2,048 mg/L. In particular, two strains with a ceftriaxone MIC above 0.5 mg/L were characterized as

Indexed as

CeftriaxoneGonorrheaAnti-Bacterial AgentsAzithromycinChinaDrug Resistance, BacterialGenomicsHumansMicrobial Sensitivity TestsNeisseria gonorrhoeaePhylogenyAnti-Bacterial AgentsAzithromycinCeftriaxone23S rRNAA2735dual resistanceF89FC428genome analysisN. gonorrhoeaepenA-60.001

Identifiers

PMID36377922
PMCPMC9769569
OpenAlexW4309048216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.